Avelumab and Merkel Cell Carcinoma: Examining the Evidence for Causation

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science information has long provided a foundational framework for understanding disease prevention and treatment across broad populations. Within this context, public health guidance and clinical education have traditionally emphasized lifestyle factors, environmental exposures, and therapeutic interventions as key determinants of health outcomes. This established body of knowledge serves as a critical reference point for evaluating emerging concerns in specialized domains, including occupational and pharmaceutical settings. Transitioning from this general health perspective, the focus now narrows to a specific therapeutic agent—avelumab—and its potential association with Merkel cell carcinoma risk. In mass production environments where avelumab is manufactured or handled, occupational exposure becomes a pertinent consideration. While the drug is approved for treating Merkel cell carcinoma, the question of causation in the opposite direction—whether avelumab exposure could contribute to the development of this rare skin cancer—requires careful examination. This pivot from general health literacy to occupational exposure concern underscores the need to assess risk profiles for workers who may encounter the compound during production, handling, or administration. The shift in emphasis moves from population-level health education to targeted occupational safety, highlighting the importance of distinguishing therapeutic benefit from potential harm in controlled exposure scenarios.

Avelumab Pharmacology and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can include conditions such as sarcoidosis, as described in a case of hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may involve the skin, gastrointestinal tract, liver, lungs, and endocrine organs. Despite these risks, avelumab therapy can often be continued with appropriate management, such as corticosteroids for irAEs (https://pubmed.ncbi.nlm.nih.gov/31543781/).

Merkel Cell Carcinoma: Clinical Presentation and Risk Factors

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of biopsy specimens, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and synaptophysin. Clinical presentation often includes a rapidly enlarging, painless, firm, red or purple nodule on sun-exposed skin, though lesions can occur anywhere on the body.

Mechanistic Pathways: Does Avelumab Cause Merkel Cell Carcinoma?

The query asks whether avelumab causes MCC. The evidence indicates that avelumab is a treatment for MCC, not a cause. The drug is specifically approved for metastatic MCC and has demonstrated efficacy in inducing tumor responses (https://pubmed.ncbi.nlm.nih.gov/29799096/). Mechanistically, avelumab enhances anti-tumor immunity by blocking PD-L1, which is often expressed on MCC cells. This action helps the immune system recognize and destroy cancer cells. There is no evidence in the provided snippets suggesting that avelumab initiates or promotes the development of MCC. Instead, the drug is used to treat existing MCC, and its use is associated with immune-related adverse events that are distinct from the cancer itself.

Adequacy of Warnings and Causation Considerations

The evidence does not directly address the adequacy of warnings about avelumab and MCC. However, the drug's approval for metastatic MCC implies that regulatory agencies have reviewed its safety and efficacy. The prescribing information for avelumab likely includes warnings about immune-related adverse events, which are common to checkpoint inhibitors. The case of sarcoidosis reactivation during avelumab treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/) underscores the need for clinicians to monitor for irAEs. There is no indication that warnings about MCC causation are necessary, as avelumab is not a known cause of MCC. For patients with MCC, the question of causation by avelumab is not supported by the evidence. Instead, patients are treated with avelumab for MCC. The drug's role is therapeutic, not etiologic. Patients who develop MCC while on avelumab for another condition would need to consider other risk factors, such as ultraviolet light exposure or Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence does not provide a basis for attributing MCC to avelumab exposure.

Timeline and Conclusion

The evidence does not describe a timeline between avelumab exposure and the development of MCC. In clinical trials, avelumab was administered to patients with established MCC, and responses were assessed over weeks to months (https://pubmed.ncbi.nlm.nih.gov/29799096/). Immune-related adverse events, such as sarcoidosis, can occur during treatment (https://pubmed.ncbi.nlm.nih.gov/31543781/), but these are not MCC. For patients who progress on avelumab, subsequent treatments like ipilimumab plus nivolumab have been studied (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/), but this does not imply causation. Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Rather, it is an approved and effective treatment for metastatic MCC. The drug's mechanism of action involves immune checkpoint inhibition, which can lead to immune-related adverse events, but not to the development of MCC. Patients and clinicians should be aware of the drug's therapeutic benefits and potential side effects, but there is no evidence to support a causal link between avelumab exposure and MCC onset.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is an approved treatment for Merkel cell carcinoma (MCC) and does not cause the disease. It works by enhancing the immune system to attack cancer cells. There is no evidence linking avelumab exposure to the development of MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the known risk factors for Merkel cell carcinoma?

Merkel cell carcinoma is associated with chronic ultraviolet light exposure and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). Other factors include immunosuppression and advanced age.

What adverse effects are associated with avelumab?

Avelumab can cause immune-related adverse events (irAEs) such as sarcoidosis, skin reactions, gastrointestinal issues, and endocrine disorders (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are manageable with corticosteroids and other interventions.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.